Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?

Alessandro Lucchesi, Silvia Carloni, Serena De Matteis, Martina Ghetti, Gerardo Musuraca, Monica Poggiaspalla, Accursio F. Augello, Giulio Giordano, Pier P. Fattori, Giovanni Martinelli, Roberta Napolitano

Research output: Contribution to journalArticle

Abstract

This study was conducted to evaluate the expression of fibrinogen receptors on platelets of Philadelphia-negative chronic myeloproliferative neoplasm (MPN) patients. We collected blood samples from 40 consecutive MPN patients and healthy volunteers. We performed flow cytometry analysis of P-selectin expression and integrin beta-3, activation of glycoprotein (GP) IIb/IIIa and fibrinogen receptor exposure (PAC-1 binding). Surprisingly, we found a very low PAC-1 binding capacity in MPN patients; however, the expression of PAC-1 was almost completely recovered with aspirin intake. We hypothesize that the hypercoagulable states observed in MPN patients could depend on a primarily plasma-driven impairment of fibrin turnover and thrombin generation.

Original languageEnglish
JournalBritish Journal of Haematology
DOIs
Publication statusAccepted/In press - Jan 1 2019

Keywords

  • aspirin
  • myeloproliferative neoplasms
  • PAC-1
  • platelet fibrinogen receptor

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?'. Together they form a unique fingerprint.

  • Cite this